The human hydroxysteroid SULT (sulphotransferase) 2B1 subfamily consists of two isoforms, SULT2B1a and SULT2B1b. These two isoenzymes are transcribed from the same gene by alternative splicing of their first exons and share 94 % amino acid sequence identity. The SULT2B1 isoforms are highly selective for the sulphation of 3β-hydroxysteroids. Immunoblot analysis of SULT2B1 expression in several human tissues indicates the presence of only SULT2B1b protein. Immunoreactive SULT2B1b protein was detected in human prostate, skin, placenta and lung tissue. SULT2B1b mRNA expression was detected in RNA isolated from term placenta, normal prostate, prostate carcinoma, benign prostate hyperplasia, LNCaP prostate cancer cells, breast cancer specimens and MCF-7 breast cancer cells. Immunohistochemical localization of SULT2B1b, in terms placental and prostate tissues, detected it in nuclei of placental syncytiotrophoblasts and cytoplasm of epithelial cells in prostate tissues. Immunoreactive and catalytically active SULT2B1b was identified in nuclei isolated from term human placenta. Also SULT2B1b was capable of translocating to nuclei in BeWo placental cells after stable transfection and differentiation. In contrast, immunohistochemical analysis of human prostate showed only cytosolic localization of SULT2B1b in the basal and luminal prostate epithelial cells. SULT2B1b was not detected in isolated nuclei from LNCaP prostate cancer cells but was present in the cytosolic fraction. Differential subcellular localization of SULT2B1b in prostate and placenta suggests that SULT2B1b may be differentially regulated and have different physiological functions in these two hormonally responsive human tissues.
INTRODUCTION
The human SULT (sulphotransferase) 2B1 family includes two isoforms, SULT2B1a and SULT2B1b, which are generated by the use of different transcriptional start sites and alternative splicing of their first exons [1] . The SULT2B1 gene is located at the same gene locus, chromosome 19q13.3, as the SULT2A1 gene, and the SULT2B1 proteins contain the hydroxysteroid SULT motif, FSSKA. Expressed SULT2B1a and SULT2B1b are selective for the sulphation of 3β-hydroxysteroids, including DHEA ( [1, 2, 6, H(N)]dehydroepiandrosterone) and pregnenolone [2] . In contrast, SULT2A1 sulphates both 3α-and 3β-hydroxysteroids, oestrogenic steroids, testosterone and a variety of xenobiotics [3] . Steroid sulphation is generally considered as an inactivation reaction since steroid sulphates do not bind and activate the appropriate steroid receptors. However, steroid sulphates may also serve as transport forms of the steroids, allowing for release of the steroid in target tissues after removal of the sulphate moiety by sulphatase activity [4] .
Functions and properties of SULT2B1a and SULT2B1b in human tissues are not well characterized. The isoforms differ in the length of their N-terminal ends: SULT2B1a has eight amino acids and SULT2B1b has 22 amino acids before their common region [1] . Expression of SULT2B1a and SULT2B1b has been reported in a number of human tissues including skin, prostate and placenta, although the expression was not detected in liver and adrenal tissues that possess high levels of SULT2A1 expression. Javitt et al. [5] , using RT (reverse transcriptase)-PCR analysis, have reported that SULT2B1a and SULT2B1b are differentially expressed in human tissues. Geese and Raftogianis [6] have reported similar results investigating SULT2B1 mRNA levels.
Abbreviations used: DHEA, [1, 2, 6, H(N)]dehydroepiandrosterone; FBS, foetal bovine serum; MEM, minimal essential medium; RT, reverse transcriptase; SULT, sulphotransferase. 1 To whom correspondence should be addressed (e-mail Charles.Falany@ccc.uab.edu).
Characterization of the expression of SULT2B1 activity or protein expression in human tissues has not been reported. In the present study, a rabbit anti-human SULT2B1 polyclonal antibody, previously raised in our laboratory [2] , was used to explore the histochemical and subcellular localization of SULT2B1a and SULT2B1b expression in human prostate and term placental tissues as well as LNCaP prostate cancer cells and BeWo placental cells. Immunoblot analysis detected the expression of only SULT2B1b in both placental and prostate tissues. Immunohistochemical and biochemical studies identified the expression of SULT2B1b in placental nuclei but not in prostate nuclei. The differential subcellular localization of SULT2B1b in these two hormonally responsive tissues may be important in understanding the role of sulphation in the regulation of hormone synthesis and function.
MATERIALS AND METHODS

Materials
Cell culture media (Mediatech, Herndon, VA, U.S.A.) were obtained from UAB Comprehensive Cancer Center Media Facility. Fugene 6 transfection reagent was purchased from Roche (Indianapolis, IN, U.S.A.). Mammalian protein extract reagent (M-PER) was purchased from Pierce (Rockford, IL, U.S.A. 
Methods
Immunoblot analysis of SULT2B1 expression in human tissues
Our laboratory has described previously the production of a rabbit anti-human SULT2B1 polyclonal antibody [2] . Although SULT2B1a and SULT2B1b are > 94 % identical in sequence, the differences in the N-terminal end of the proteins allow for separation and identification of the proteins via immunoblot analysis. The IgG fraction of the rabbit anti-SULT2B1 antibody was obtained by Protein A chromatography [7] and subsequently immunoaffinity-purified using pure expressed SULT2B1b, covalently attached to CNBr-activated Sepharose 4B [7] .
Human tissue specimens (liver, skin, prostate, placenta, colon, lung, kidney and adrenal) were stored at − 110
• C and analysed within 6 months of procurement. Tissue samples were thawed in 10 mM sodium phosphate buffer (pH 7.4), 10 % (v/v) glycerol, 1.5 mM dithiothreitol and complete, mini protease inhibitor cocktail (Roche) and homogenized. Homogenates were centrifuged at 100 000 g for 1 h and the resulting cytosolic preparations were used for immunoblot analysis. Protein concentrations were estimated using the Bio-Rad protein assay system with γ globulin as a protein standard. Tissue cytosols were resolved by SDS/PAGE and electrotransferred on to nitrocellulose membranes [8] . Membranes were blocked with 5 % (w/v) non-fat milk, and then incubated with rabbit polyclonal anti-SULT2B1a antibody for 2 h at the appropriate dilutions. Goat anti-rabbit IgG horseradish peroxidase conjugate (1:60 000) was used as the secondary antibody and visualization of bound proteins was performed using the SuperSignal West Pico System (Pierce). At least four individual specimens of each tissue have been analysed by immunoblot analysis.
Northern-blot analysis of SULT2B1 mRNA expression Total RNA was isolated from normal prostate, benign prostate hyperplasia, prostate carcinoma, lung, breast cancer tissue, placental tissue, LNCaP cells and MCF-7 cells using STAT-60. Aliquots (20 µg) of total RNA were mixed with 3 vol. of RNA gel loading buffer (Ambion, Austin, TX, U.S.A.), and resolved in 1 % agarose-formaldehyde denaturing gels. RNA was then transferred on to a nitrocellulose membrane with a rapid downward transfer device (Schleicher and Schuell, Keene, NH, U.S.A.) and covalently bound to the membrane with UV irradiation in a BioRad Genelinker. For use as a probe, the SULT2B1b cDNA was isolated from the pcDNA3.1-SULT2B1b plasmid by digestion with EcoRI and HindIII, then resolved and purified in agarose gel. The SULT2B1b cDNA was labelled with [α-32 P]dCTP using a Prime It II random primer labelling kit (Stratagene) to a specific activity of approx. 2.5 × 10 6 c.p.m./ng. RNA-bound membrane was hybridized with the SULT2B1b cDNA probe in Quickhyb solution at 68
• C for 2 h. Subsequently, the membrane was washed twice in 2 × SSC/0.1 % SDS (2 × SSC: 0.3 M NaCl/0.03 M sodium citrate, pH 7.0) for 15 min at room temperature (approx. 23-25
• C) and then twice in 0.1 × SSC/0.1 % SDS (0.1 × SSC: 15 mM NaCl/1.5 mM sodium citrate, pH 7.0) for 15 min at 60 • C. The membrane was then exposed overnight to an autoradiograph film at − 70
• C with an intensifying screen. To analyse the specific expression of SULT2B1a and SULT2B1b mRNAs, oligonucleotides specific to the 5 -sequences of the cDNAs were used. The oligonucleotides (SULT2B1a, 5 -CTTCTGGCTGTGGAAAGGTGGGGGAGACGC-3 ; SULT2B1b, 5 -TGTCATCTTCATAGGTGTCCCACAAGCC-3 ) were labelled with [γ -32 P]ATP using an RTS T4 kinase labelling system (Life Technologies) for use as probes. poly(A) + (polyadenylated) RNA was isolated using the Oligotex mRNA mini kit. poly(A) + RNA was resolved by agarose gel electrophoresis in the presence of formaldehyde and transferred on to a nitrocellulose membrane. RNA was bound to the membranes using UV irradiation and then hybridized with the γ -32 P-ATP-labelled SULT2B1-specific oligonucleotides (2.5 × 10 6 c.p.m./ml) in Quickhyb for 2 h. Membranes were hybridized as described previously and autoradiography was performed at − 70
• C with an intensifying screen.
Immunohistochemical localization of SULT2B1b
Paraffin blocks of human placenta and prostate tissues were obtained from the UAB Tissue Procurement Service. The blocks were cut into 4-5 µm sections and attached to glass slides by melting at 58
• C. Tissue sections were placed in 10 mM citrate buffer (pH 6.0) and boiled for 8 min in a microwave for antigen retrieval. Endogenous peroxidase activity was quenched with 3 % H 2 O 2 and the slides were then placed in humidity chambers with 1 % goat serum for 1 h. Slides were drained and incubated in the humidity chamber with either 1 % goat serum (control) or a 1:660 dilution of rabbit anti-SULT2B1a IgG (1.3 mg/ml) for 1 h. Tissue sections were then labelled using a biotin-streptavidin system (USA HRP Test System) and visualized by the addition of the chromogenic substrate 3,3-diaminobenzidine tetrahydrochloride. Slides were counterstained in haematoxylin and covered with a glass coverslip. Photographs were taken using a Nikon 20 × 40 imaging system.
Nuclei isolation
To confirm the localization of SULT2B1b in placental nuclei, nuclei from human term placenta were isolated by the method of Warriar et al. [9] . For the preparation of intact placental nuclei, fresh placenta (post-delivery < 10 h) was cleaned after removing clotted blood, umbilical cord and extraneous membranes. A placenta was then cut into smaller pieces and homogenized in a large, chilled commercial blender with buffer A (40 mM Tris/HCl, pH 7.5/0.25 M sucrose/5 mM EDTA/2.5 mM PMSF/ 7 mM 2-mercaptoethanol) for 4 × 30 s at 1 min intervals. The homogenate was centrifuged at 1000 g for 15 min at 4
• C to collect the crude nuclear pellet. The pelleted fraction was resuspended in buffer B (25 mM Hepes/5 mM KCl/0.5 mM MgCl 2 /1 mM PMSF/10 % glycerol/1 mM dithiothreitol) and centrifuged again at 1000 g for 15 min at 4
• C. The pellet was resuspended in buffer C (buffer B with 0.01 % Nonidet P40) and filtered through three layers of gauze. The filtrate was centrifuged at 1000 g for 15 min at 4
• swinging-bucket rotor at 10 000 g for 40 min at 4
• C. Placental nuclei were collected at the 30-35 % Optiprep interface after centrifugation. Nuclei from LNCaP and transfected stable BeWo cells were isolated using the same Optiprep-gradient procedure, whereas cytosolic and microsomal fractions were prepared by centrifugation at 100 000 g from the resulting supernatant fraction after collection of the crude nuclei fraction. SULT2B1b was identified in the isolated fractions by immunoblot analysis and DHEA sulphation activity. DHEA sulphation activity was assayed as described by Meloche and Falany [2] . Nuclei were also identified using immunoblot analysis with mouse anti-histones monoclonal antibody.
Transfection of BeWo cells
BeWo placental choriocarcinoma cells do not endogenously express detectable levels of SULT2B1b. To investigate the localization of SULT2B1b, BeWo cells were transfected with SULT2B1b. BeWo cells were maintained in MEM (minimal essential medium) with Earle's salts and L-glutamine supplemented with 10 % (v/v) FBS (foetal bovine serum). The fulllength SULT2B1b open reading frame was amplified by PCR Pfu polymerase using the forward primer 5 -GATTCGAATTCGG-CATGGACGGG-3 , incorporating an EcoRI site and the reverse primer 5 -GACGGTCAAGCTTATTATGAGGGTCGTGGG-3 , incorporating a HindIII site. The amplified SULT2B1b cDNA was restricted, purified and ligated into the mammalian expression vector pcDNA3.1(−). The pcDNA3.1-SULT2B1b plasmids were transfected into 50 % confluent BeWo cells using Fugene 6 reagent at a DNA/reagent mixture ratio of 1:3 in OPTI-MEM (Invitrogen). OPTI-MEM was replaced with MEM with 10 % FBS 8 h post-transfection. After 48 h, the transfected BeWo cells were placed in MEM with 10 % FBS medium and 400 µg/ml Geneticin. Media were changed daily until single colonies appeared. Colonies were isolated and expanded in 24-well plates until confluence. For the forskolin-stimulated differentiation studies, SULT2B1b/BeWo cells were grown to approx. 70 % confluence. The cells were then treated with MEM + vehicle (DMSO) or MEM + forskolin (100 µM) for up to 96 h with daily renewal of media. Time points of differentiation were taken to detect SULT2B1b expression in nuclei and cytosol by immunoblot analysis and DHEA sulphation assays.
RESULTS
Immunoblot analysis of SULT2B1 expression in human tissues
Immunoblot analysis of several human tissues was performed using the rabbit anti-SULT2B1 antibody to determine the levels of SULT2B1a and SULT2B1b expression. Because of the molecular mass difference between the SULT2B1 isoforms, the antibody is capable of discriminating between the isoforms during immunoblot analysis [2] . Figure 1 shows that only SULT2B1b is detected in human skin, prostate, placenta and lung tissues by immunoblotting. SULT2B1a was not detected in any of the tissues examined. SULT2B1 isoform was not detected in the liver, kidney, colon or adrenal tissues. Also, the SULT2B1b isoform migrated with the same molecular mass as the bacterially expressed enzyme during SDS/PAGE, suggesting that there were no major secondary modifications to the enzyme.
Northern-blot analysis of SULT2B1b mRNA expression in human tissues
Total RNA and poly(A) + RNA were isolated from human tissues including normal prostate, benign prostate hyperplasia, prostate
Figure 1 Immunoblot analysis of SULT2B1b in human tissues
Cytosolic protein (100 µg) was prepared from several representative human tissues, resolved by SDS/PAGE (12 % gel) and electrotransferred on to a nitrocellulose membrane. The membrane was incubated with rabbit anti-SULT2B1 IgG and then with goat anti-rabbit IgG horseradish peroxidase conjugate. Lane carcinoma, LNCaP cells, lung, MCF-7 cells, breast adenocarcinoma and term placenta. Northern-blot analysis of the RNA samples was performed using 32 P-labelled SULT2B1b cDNA as well as SULT2B1a-and SULT2B1b-specific oligonucleotides. Figure 2 (A) shows that in blots of total RNA hybridized with the SULT2B1b cDNA, same size mRNAs were detected in RNA from normal prostate, prostate adenocarcinoma, benign prostate hyperplasia, LNCaP cells, breast cancer adenocarcinoma, MCF-7 breast cancer cells as well as lung and term placental tissues. SULT2B1 mRNA could be easily detected in RNA from all these tissues; however, the level of hybridization was greater in the normal and cancerous prostate samples and in the placental specimen. Figure 2(B) shows that in blots of poly(A) + RNA isolated from term placenta, LNCaP cells, benign prostate hyperplasia, prostate adenocarcinoma, prostate intraepithelia neoplasia, MCF-7 cells and breast adenocarcinoma hybridized with the SULT2B1b-specific oligonucleotide, SULT2B1b mRNA could be easily detected. Under similar conditions, no detectable mRNA was observed with the SULT2B1a-specific oligonucleotide probe (results not shown). The hybridization results with the SULT2B1 isoform-specific oligonucleotides are consistent with the lack of detection of SULT2B1a protein in human tissues by immunoblot analysis.
Immunohistochemical localization of SULT2B1b in placenta and prostate
Immunolocalization of SULT2B1b was performed in human prostate and term placental tissues. SULTs involved in steroid and 
Figure 4 Immunoblot analysis of subcellular fractions isolated from human placenta
Nuclei were isolated from fresh human placenta using an Optiprep gradient as described in the Materials and methods section. Isolated fractions were analysed by immunoblot analysis using rabbit anti-SULT2B1b IgG and mouse anti-histone monoclonal antibody. (A) Results with rabbit anti-SULT2B1 IgG. Lane 1, expressed SULT2B1a (lower band) and SULT2B1b (upper band); lane 2, cytosol (100 µg) prepared from placental tissue using a standard cytosol preparation procedure [8] ; lane 3, isolated nuclei (10 µg); lane 4, the supernatant fraction (100 µg) generated during the placental nuclei isolation procedure; lane 5, the microsomal fraction (100 µg) obtained after the isolation of the nuclei-containing fraction. (B) Immunoblot analysis of the same fractions using mouse anti-histone monoclonal IgG. Lane 1, supernatant fraction (100 µg) generated during the placental nuclei isolation procedure; lane 2, initial nuclei pellet of placental homogenate; lane 3, isolated nuclei (5 µg); lane 4, microsomal fraction (100 µg) obtained after the isolation of the nuclei-containing fraction.
drug metabolism were thought to be localized in the cytoplasm of cells [10] . Figure 3(A) shows the immunolocalization of SULT2B1b in term placental tissue using immunoaffinity-purified rabbit anti-human SULT2B1 IgG. SULT2B1-specific staining was detected in the nuclei of placenta syncytiotroblast cells. Very little staining was observed in the cytoplasm of cells in the placental sections. In contrast, Figure 3(B) shows the presence of SULT2B1b staining in the cytoplasm of basal and luminal epithelial cells in benign hyperplastic prostate. In contrast with placenta, no obvious staining was observed in the nuclei of the epithelial cells in the prostate specimen.
Analysis of the subcellular localization of SULT2B1b
To confirm the expression of SULT2B1b in the nuclei of term placental cells, nuclei were isolated from fresh term human placental tissue by homogenization and gradient centrifugation. Intact nuclei were collected from the interface of the 30-35 % Optiprep layers after centrifugation. The presence of SULT2B1b in the nuclear fractions was determined by immunoblot analysis and DHEA sulphation activity. Figure 4(A) shows the presence of immunoreactive SULT2B1b in the nuclear fraction obtained from the To confirm that SULT2B1b was present and active in nuclei, freshly isolated intact placental nuclei were assayed for DHEA sulphation activity. Table 1 shows that the gradientpurified placental nuclei fraction possessed high levels of DHEA sulphation activity. DHEA sulphation activity was also detected in the 30 % Optiprep fraction or 'light fraction' immediately above the 30-35 % interface; this fraction also contained immunoreactive SULT2B1b. The initial placental homogenate used in the isolation of the intact nuclei had a low level of DHEA sulphation activity, whereas no activity was detected in the supernatant fraction prepared from the placental homogenate after the initial isolation of intact nuclei. Northern-blot and immunoblot analyses of the placental samples did not detect any expression of SULT2A1 that also has DHEA sulphation activity. DHEA sulphation activity was no longer detected in the cytosol or the suspended pellet of the isolated nuclei after homogenization and ultracentrifugation.
Immunocytochemical analysis of SULT2B1b in transfected BeWo cells
Human BeWo placental cells do not possess detectable SULT2B1b mRNA or immunoreactive protein expression. Also, BeWo cells do not contain DHEA sulphation activity or immuoreactive SULT2A1. To investigate further the subcellular localization of SULT2B1b, BeWo cells were stably transformed with the SULT2B1b cDNA subcloned into the pcDNA3.1(−) mammalian expression vector. After transformation, colonies of Geneticin-resistant BeWo cells were isolated and cultured for analysis of SULT2B1b expression. BeWo cells can also be stimulated to differentiate into syncytiotrophoblast-like cells by forskolin treatment [11] . Figure 5(A) shows the increase in BeWo cells with a small stellate shape after forskolin treatment, indicating an increase in the differentiated phenotype.
To investigate the effect of differentiation on SULT2B1b nuclear localization in stably transformed BeWo cells, the levels of immunoreactive SULT2B1b in isolated nuclei and cell cytosol were analysed for 4 days after forskolin treatment. Figure 5(B, d) shows the immunoblot analysis of SULT2B1b expression in nuclei and cytoplasm of forskolin-treated BeWo cells stably expressing SULT2B1b. Cells were treated with forskolin starting on consecutive days so that the control cells were cultured for the same time period as the treated cells. Only a low level of immunoreactive SULT2B1b was detected in the nuclei of untreated BeWo cells, although significant levels were detected in cytosol from the same cells treated with forskolin. The amount of immunoreactive SULT2B1b detected in nuclei of BeWo cells treated with forskolin also increased in a time-dependent manner. High levels of SULT2B1b were found in both nuclei and cytosol, 72 h after forskolin treatment. Figure 5(B) shows the immunoblot analysis of histone expression in the forskolin-treated BeWo cells stably expressing SULT2B1b. Histone immunoreactivity was observed only in the isolated nuclei preparation. As expected, no detectable histone immunostaining was observed in the cytosolic fractions.
Immunoblot analysis of subcellular fractions prepared from LNCaP cells and SULT2B1-transfected BeWo cells
Almost confluent cultured LNCaP cells and stably transfected SULT2B1b-BeWo cells were harvested and nuclear pellets were obtained by low-speed centrifugation [9] . Microsomal and cytosolic fractions were obtained from the supernatant fraction after isolation of the crude nuclear pellet. Intact nuclei were isolated from the crude nuclear pellet by the Optiprep-gradient centrifugation procedure. Figure 6 shows the immunoblot analysis of SULT2B1b and histone expression in the isolated nuclei, microsomal and cytosolic fractions. In LNCaP cells, SULT2B1b was detected only in the cytosolic fraction ( Figure 6A ). No immunoreactive SULT2B1b was detected in the intact isolated nuclei or in the microsomal fraction. In SULT2B1b stably transfected BeWo cells, immunoreactive SULT2B1b was detected not only in intact nuclei but also in the cytosolic and microsomal fractions ( Figure 6C ). Histone immunoreactivity was detected only in the isolated LNCaP and BeWo nuclei (Figures 6B and  6D ).
DHEA metabolism in LNCaP cell lines
A characteristic of SULT2B1b is that the enzyme is very labile and loses steroid sulphation activity during homogenization and preparation of tissue and cell cytosol or homogenates [2] . Figure 7 shows the ability of intact LNCaP cells to generate DHEA sulphates when incubated with 3 H-labelled DHEA in the medium. LNCaP cells express SULT2B1b (Figure 6 ) but do not express SULT2A1 or SULT2B1a, indicating that SULT2B1b is responsible for the DHEA sulphation activity in these cells. Cytosol prepared from the LNCaP cells showing DHEA sulphation activity as well as the presence of immunoreactive SULT2B1b did not show any detectable DHEA sulphation activity. Similar 
DISCUSSION
The present study describes several aspects of the expression, regulation and subcellular localization of SULT2B1b in human placenta and prostate tissues. Using a rabbit anti-SULT2B1 polyclonal antibody that can distinguish between SULT2B1a and SULT2B1b during immunoblot analysis, only the expression of immunoreactive SULT2B1b was detected in several human tissues ( Figure 1 ). Her et al. [1] have reported the expression of the SULT2B1 mRNAs in human placenta and prostate tissues by Northern-blot analysis using the full-length SULT2B1a cDNA. They also reported the presence of greater levels of SULT2B1b mRNA in these tissues when compared with SULT2B1a after RACE (rapid amplification of cDNA ends) analysis. Owing to the high identity (94 %) shared by SULT2B1a and SULT2B1b, SULT2B isoform-specific oligonucleotides were utilized in the present study to distinguish between the mRNA expressions of the two isoforms. Northern-blot analysis detected abundant SULT2B1b mRNA in human placenta, prostate, prostate cancer tissue, prostate cancer LNCaP cells, breast cancer tissue, MCF-7 breast cancer cells and lung. In contrast, no SULT2B1a mRNA was detected by Northern-blot analysis for the SULT2B1a-specific oligonucleotide. Geese and Raftogianis [6] reported amplification of SULT2B1b, but not SULT2B1a, mRNA by RT-PCR analysis using isoform-selective primers in human placenta and prostate tissues. The low level of SULT2B1a mRNA expression in human tissues is supported by the lack of detectable immunoreactive SULT2B1a protein. Fuda et al. [12] have suggested that SULT2B1b is responsible for cholesterol sulphation and SULT2B1a is responsible for pregnenolone sulphation. They have identified both SULT2B1 mRNAs in several human tissues by RT-PCR. The lack of detectable immunoreactive SULT2B1a protein in the human tissues examined, as well as the low levels of SULT2B1a mRNA expression, indicates that SULT2B1b is the physiologically relevant SULT2B1 isoform in most human tissues; however, it is possible that low levels of SULT2B1a may be expressed in selected human tissues. The localization of SULT2B1b in the nuclei of term placental syncytiotrophoblasts is the initial indication of the nuclear localization of a 'cytosolic' SULT isoform. Stanley et al. [13] have reported the immunolocalization of SULT1A isoforms in the cytosol of syncytiotrophoblasts of human placenta. However, they did not c 2004 Biochemical Society examine in their studies if there was immunostaining in nuclei. In support of the immunohistochemical localization of SULT2B1b in nuclei of syncytiotrophoblasts, SULT2B1b-immunoreactive protein and activity were detected in purified intact term human placental nuclei. No SULT2B1b expression was observed in the cytosol or microsomes obtained after isolation of the nuclei. In contrast with the placenta, in prostate tissue with benign hyperplasia, SULT2B1b was immunohistochemically localized only to the cytoplasm of epithelial cells. Also, in LNCaP prostate cancer cells, SULT2B1b protein was detected only in the cytosol and no immunoreactive protein was present in purified nuclei. These results indicate that the regulation and roles of SULT2B1b in hydroxysteroid metabolism may be different in hormoneresponsive tissues.
The placenta provides a mechanism for nutrient transfer between the foetus and the maternal circulation as well as the establishment of the unique hormonal environment required for foetal development during pregnancy. The placenta synthesizes and secretes large amounts of oestrogens and progesterone. Progesterone is synthesized in the placenta from cholesterol, whereas oestrogens are synthesized from adrenal androgen precursors. Approx. 90 % of estriol and 50 % of estrone and β-estradiol is synthesized in the mature placenta at the time of pregnancy [14] . Synthesis of oestrogens depends on the supply of external precursors, such as DHEA-3-sulphate and 16α-OH-DHEA-sulphate [14] . DHEA-3-and 16α-OH-DHEA-sulphates are desulphated in placenta cells by membrane-bound sulphatase before conversion into oestrogens [15, 16] . Although large amounts of C 19 steroids and progesterone are present in the maternal circulation, only low levels of these steroids are present in the foetal circulation owing to selective retention in the maternal circulation. The specific expression of SULT2B1b in the nuclei of syncytiotrophoblast may have to occur to prevent binding and selective activation of steroid receptors in syncytiotrophoblast nuclei. Also, the SULT2B1b immunolocalization studies were performed with term placenta and the nuclear localization may be specifically associated with or stimulated by parturition.
BeWo cells are a human choriocarcinoma cell line that responds to forskolin treatment with differentiation to a more syncytiotrophoblast phenotype [17, 18] . Tamura et al. [19] have reported that SULT2A1 mRNA, but not SULT2B mRNA, was detected in BeWo cells by RT-PCR. In this and previous studies [20] , no expression of SULT2A1 or the SULT2B1 isoforms was detected in BeWo cells by immunoblot analysis or DHEA sulphation activity. Stable transfection of BeWo cells with SULT2B1b allowed for the localization of SULT2B1b in isolated BeWo nuclei. In transfected BeWo cells, SULT2B1b was also found in microsomes and cytosol. The presence of SULT2B1b in BeWo microsomes may be an artifact of the high levels of expression or the result of binding to proteins in the endoplasmic reticulum involved in nuclear localization. Additionally, SULT2B1b localization in nuclei could be stimulated in stably transfected BeWo cells by forskolin-stimulated differentiation. These results suggest that SULT2B1b localization involves binding and transport to the nuclei via interaction with proteins in the endoplasmic reticulum. These interactions would most probably involve the unique proline-rich carboxy end of the protein.
The mechanism for the nuclear localization of SULT2B1b in placenta is not known; however, SULT2B1b is unique among the cytosolic SULTs due to the presence of approx. 50 amino acids on the carboxy end of the protein [1] . This unique region is rich in proline-charged amino acid repeats. Analysis of the human SULT amino acid sequences using the PSORT II localization program indicates that among the human SULTs, only SULT2B1b has an amino acid composition indicative of a tendency for nuclear localization (for prediction of protein sorting signals and localization sites in amino acid sequences, visit http://psort.ims.utokyo.ac.jp/form2.html).
In contrast with placenta, immunoreactive SULT2B1b appears to be expressed in the cytoplasm of epithelial cells in normal prostate, prostate with benign hyperplasia, prostate intraepithelial neoplasia and prostate adenocarcinoma cells (results not shown). No apparent expression of SULT2B1b was detected in nuclei during the immunolocalization studies using the different prostate tissues. SULT2B1b is normally expressed in LNCaP prostate adenocarcinoma cells; however, no SULT2B1b was detected in nuclei isolated from the LNCaP cells. SULT2B1b was present in the cytosolic fraction of LNCaP prepared during the nuclei isolation procedure, but not in microsomes prepared at the same time. In prostate epithelial cells, SULT2B1b may have a role in the sulphation of DHEA and prevention of its conversion into testosterone or dihydrotestosterone. Labrie et al. [4, 21] have reported that human prostate epithelial cells are capable of converting DHEA into dihydrotestosterone. Sulphation of DHEA would prevent the intracellular conversion of DHEA into androgens and allow for prostate regulation by testicular androgens. The different sites of SULT2B1b expression in placenta and prostate suggest that its physiological function may be different.
One characteristic of SULT2B1b is the loss of activity in tissues and cells after homogenization. DHEA sulphation activity was detected in both intact isolated placental nuclei and LNCaP cells but was lost after homogenization of the organelles or cells. Meloche and Falany [2] have reported difficulty in expressing active wild-type SULT2B1b in Escherichia coli, whereas the presence of an N-terminal His tag allows expression and isolation of the active enzyme. The presence of the His tag also altered the kinetic properties of both SULT2B1a and SULT2B1b when compared with the native forms of the enzymes. The properties and structure of SULT2B1b suggest that protein-protein interactions are important for its regulation and localization. The mechanism and regulation of nuclear transport and activity of SULT2B1 in placental and prostate cells is currently being investigated.
The present study on SULT2B1b suggests that physiological roles of the enzyme may also be dependent on the intracellular localization of the enzymes in selected tissues. The localization of SULT2B1b in nuclei in term placenta, but not in adult normal and diseased prostate, suggests another level of regulation of the enzyme. Regulation of the SULT2B1 family also includes an apparent lack of detectable SULT2B1a protein expression. These findings also indicate that a closer examination of the tissuespecific intracellular localization and functional expression of other members of the cytosolic SULT gene family is needed.
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